Back to Home

Data Ownership Is A Major Competitive Advantage For RegenMed and Its Clients

February 28, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Data Ownership Is A Major Competitive Advantage For RegenMed and Its Clients

June 9, 2025

Data: The World’s Most Precious Commodity

In the 21st Century, data is the raw material upon which all value-added transactions depend.  Manufacturing, finance, transportation, energy and countless other industries all heavily rely on data to innovate, compete and indeed survive.  This is nowhere more true than in healthcare.  The $60 billion healthcare data market is growing at over 11% per year. 1  

The largest consumer of data will be AI, if it is not already.  Indeed, AI is fast running out of training data. 2 This puts a premium on private sources of relevant and high-quality data.  As with all raw material, clear proof of data ownership is critical.  

Who Owns That Data?

Failure to establish data ownership invites litigation, and the inability to successfully monetize or otherwise use it.  For example, in December 2023 the New York Times sued OpenAI and Microsoft for copyright infringement, seeking billions of dollars in damages. 3

This month, Thomson Reuters won a landmark AI copyright infringement case.  The federal court held that the defendant used content from Thomson Reuters to develop a competing AI-driven legal research tool.  The judge ruled that the defendant’s actions did not qualify as "fair use" under U.S. copyright law.  This landmark decision underscores the legal protections surrounding the use of copyrighted materials in AI training and development.

This Is Yet One More Challenge For “Big Data” And Healthcare AI Models

AI in medicine is already here, and will only become more pervasive.  However, the data on which AI healthcare models train is typically of poor quality.  Problems include incompleteness, inability to audit original sources, no or irrelevant clinical context, data “cleaning” and other unknown manipulations, irreconcilable data conflicts, no correlated outcomes measures, and stale or undated information.  

Most of today’s $60 bn. data market represents the exchange and repackaging of such “big data”. 4 AI error rates and “hallucinations” are thus not only inevitable in most AI healthcare solutions, they are dangerous in specific applications such as clinical decision-making. 5  

But now there is a deeper problem – who owns the various bits and pieces of data making up a “big data” dataset?  EMR companies, medical society registries, hospital systems, researchers, payers, AI start-ups are among the many entities who may have contributed and will claim ownership.  The weaknesses of “big data” structures, coupled with competing ownership claims, will make it an increasingly unattractive choice for healthcare data consumers, including AI models.    

The Circles Solution

RegenMed’s Circle datasets are generated and maintained in a closed system which maintains their coherence, transparency, and auditability.  They are high-quality – both statistically and clinically significant – with clear ownership and monetization rights vested in the dataset creators.

Real world data is likely to become one of the most critical categories of all healthcare data.  It will be key to supporting value-based medicine, lower costs, faster lab-to-bedside clinical translation, and health equity.  RegenMed is well positioned to capture a significant portion of this market.


‍

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Data Ownership Is A Major Competitive Advantage For RegenMed and Its Clients

February 28, 2025

Data: The World’s Most Precious Commodity

In the 21st Century, data is the raw material upon which all value-added transactions depend.  Manufacturing, finance, transportation, energy and countless other industries all heavily rely on data to innovate, compete and indeed survive.  This is nowhere more true than in healthcare.  The $60 billion healthcare data market is growing at over 11% per year. 1  

The largest consumer of data will be AI, if it is not already.  Indeed, AI is fast running out of training data. 2 This puts a premium on private sources of relevant and high-quality data.  As with all raw material, clear proof of data ownership is critical.  

Who Owns That Data?

Failure to establish data ownership invites litigation, and the inability to successfully monetize or otherwise use it.  For example, in December 2023 the New York Times sued OpenAI and Microsoft for copyright infringement, seeking billions of dollars in damages. 3

This month, Thomson Reuters won a landmark AI copyright infringement case.  The federal court held that the defendant used content from Thomson Reuters to develop a competing AI-driven legal research tool.  The judge ruled that the defendant’s actions did not qualify as "fair use" under U.S. copyright law.  This landmark decision underscores the legal protections surrounding the use of copyrighted materials in AI training and development.

This Is Yet One More Challenge For “Big Data” And Healthcare AI Models

AI in medicine is already here, and will only become more pervasive.  However, the data on which AI healthcare models train is typically of poor quality.  Problems include incompleteness, inability to audit original sources, no or irrelevant clinical context, data “cleaning” and other unknown manipulations, irreconcilable data conflicts, no correlated outcomes measures, and stale or undated information.  

Most of today’s $60 bn. data market represents the exchange and repackaging of such “big data”. 4 AI error rates and “hallucinations” are thus not only inevitable in most AI healthcare solutions, they are dangerous in specific applications such as clinical decision-making. 5  

But now there is a deeper problem – who owns the various bits and pieces of data making up a “big data” dataset?  EMR companies, medical society registries, hospital systems, researchers, payers, AI start-ups are among the many entities who may have contributed and will claim ownership.  The weaknesses of “big data” structures, coupled with competing ownership claims, will make it an increasingly unattractive choice for healthcare data consumers, including AI models.    

The Circles Solution

RegenMed’s Circle datasets are generated and maintained in a closed system which maintains their coherence, transparency, and auditability.  They are high-quality – both statistically and clinically significant – with clear ownership and monetization rights vested in the dataset creators.

Real world data is likely to become one of the most critical categories of all healthcare data.  It will be key to supporting value-based medicine, lower costs, faster lab-to-bedside clinical translation, and health equity.  RegenMed is well positioned to capture a significant portion of this market.


‍

1 Big Data in Healthcare Market Size, Global Trends, Share, Forecast to 2033

2 Have AI Companies Run Out of Training Data? Elon Musk Thinks So

3 New York Times Files Copyright Lawsuit Against AI Tech Companies

4 Top 10 Challenges of Big Data Analytics in Healthcare

5 Hallucinations in AI-generated medical summaries remain a grave concern

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.